Aldagen gets $18.4M in fourth round

With the help of Intersouth Partners, Tullis-Dickerson, Harbert Venture Partners and The Aurora Funds, stem cell technology company Aldagen has closed an $18.4 million fourth round of funding. The company plans to use the funding to to advance four clinical-stage product candidates and for general corporate purposes. Durham, NC-based Aldagen has been developing adult stem cell therapies for leukemia, damaged heart muscles and other ailments.

- check out Aldagen's release
- read this report for more

ALSO: Malvern, PA-based CRO Frontage Laboratories has raised $10 million in growth equity funding. Release

Suggested Articles

Across its 15-year history, Omega Funds has a hand in a clutch of high-profile biotechs such as Editas Medicine and Juno Therapeutics.

After Novartis’ near $10 billion buyout of The Medicines Company, many thought cardiovascular therapies were hot again.

The data position Leo to file for approval of the Dupixent rival in atopic dermatitis next year.